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Abstract
Background Patients with chronic obstructive pulmonary
disease (COPD) are at elevated risk of pneumococcal infec-
tion. A 13-valent pneumococcal conjugate vaccine (PCV13)
was approved for protection against invasive disease and
pneumonia caused by Streptococcus pneumoniae in adults.
This study estimated the incremental cost-effectiveness ratio
(ICER) of vaccinating COPD patients C50 years old with
PCV13 comparedwith current vaccination policy (CVP) with
23-valent pneumococcal polysaccharide vaccine.
Methods A Markov model accounting for the risks and
costs for all-cause non-bacteremic pneumonia (NBP) and
invasive pneumococcal disease (IPD) was developed. All
parameters, such as disease incidence and costs (€; 2015
values), were based on published data. The perspective of
the analysis was that of the Spanish National Healthcare
System, and the horizon of evaluation was lifetime in the
base case. Vaccine effectiveness considered waning effect
over time. Outcomes and costs were both discounted by
3 % annually.
Results Over a lifetime horizon and for a 629,747 COPD
total population, PCV13would prevent 2224 cases of inpatient
NBP, 3134 cases of outpatientNBP, and 210 IPDextra cases in
comparisonwith CVP. Additionally, 398 related deaths would
be averted. The ICERwas €1518 per quality-adjusted life-year
(QALY) gained for PCV13 versus CVP. PCV13 was found to
be cost effective versus CVP from a 5-year modelling horizon
(1302 inpatient NBP and 1835 outpatient NBP cases together
with 182 deaths would be prevented [ICER €25,573/QALY]).
Univariate and probabilistic sensitivity analyses confirmed the
robustness of the model.
Conclusions At the commonly accepted willingness-to-
pay threshold of €30,000/QALY gained, PCV13 vaccina-
tion in COPD patients aged C50 years was a cost-effective
strategy compared with CVP from 5 years to lifetime
horizon in Spain.
Key Points
The administration of 13-valent pneumococcal
conjugate vaccine (PCV13) in a C50 years of age
chronic obstructive pulmonary disease (COPD)
cohort would have higher health benefits than the
current vaccination policy with polysaccharide
vaccine in Spain.
The incremental costs of this vaccination strategy are
counterbalanced in part by savings from averted
pneumococcal disease cases.
Vaccination with PCV13 in COPD patients




1 Department of Pneumology, Hospital Universitario Gregorio
Maran˜o´n, Madrid, Spain
2 Department of Pneumology, Hospital Universitario La Fe,
Valencia, Spain
3 Preventive Medicine and Epidemiology Department,
Hospital Universitari Vall d’Hebron, Barcelona, Spain
4 Medical Department, Pfizer SLU, Alcobendas, Madrid, Spain
5 Pharmacoeconomics and Outcomes Research Iberia, Madrid,
Spain
6 Health Economics and Outcomes Research Department,
Pfizer SLU, Avda. de Europa, 20-B, Parque Empresarial La
Moraleja, 28108 Alcobendas, Madrid, Spain
7 Department of Economics, University of La Rioja, Logron˜o,
Spain
Clin Drug Investig (2016) 36:41–53
DOI 10.1007/s40261-015-0345-z
1 Introduction
Streptococcus pneumoniae is a major cause of morbidity,
mortality, and associated costs in the adult population [1].This
bacterium causes different disease manifestations, including
invasive pneumococcal disease (IPD) and non-invasive
mucosal infections (non-IPD) and non-bacteremic pneumonia
(NBP).Older adults and thosewith certain clinical conditions,
such as those with immunocompromising conditions and
immunocompetent patients with chronic diseases, are at
increased risk of developing pneumococcal disease (PD),
particularly pneumonia, along with having a higher risk of
related mortality [2, 3]. In particular, one of the most relevant
underlying conditions associated with increased risk for PD is
chronic obstructive pulmonary disease (COPD) [4]. Adults
with COPD run more than a four-fold increased risk of PD
than patients without this condition [5, 6].
All-cause NBP constitutes between 5 and 12 % of all
respiratory tract infections in the adult population [7], with
an estimated annual incidence rate in Spain of 3 cases per
1000 adult habitants [8], which means 114,000 annually
diagnosed pneumonias throughout the country (for an adult
population estimated to be 38,162,985 in the year 2014
[9]). Approximately 41.5 % of all NBP cases require
hospitalization [8], with an associated disease fatality rate
of 17.4 % [10]. Gil-Prieto and colleagues [10] identified
75,932 deaths due to NBP among hospitalized patients
aged 50 years or older in the period 2003–2007. The esti-
mated cost per pneumonia management case was €568.43
[8] for outpatient NBP and €2465 and €5534 by series [8,
10], with a total annual cost due to these hospitalizations
estimated to be more than €479 million. As the only health
policy intervention that reduces the high burden of PD [11],
vaccination strategies have been established in almost all
European countries for those at high risk and/or the elderly
population [12]. In Spain, current vaccination policy (CVP)
recommends 23-valent pneumococcal polysaccharide
(PPV23) or 13-valent pneumococcal conjugate (PCV13)
vaccination for high-risk adults of all ages (immunocom-
promised patients and those with chronic diseases) and,
depending on the region, for the population C60
or C65 years old [13]. A review of Spanish pneumococcal
vaccination recommendations for adults performed by 16
scientific societies and published in 2013 concluded that
non-conjugated polysaccharide vaccines are less immuno-
genic than conjugated vaccines and their efficacy decreases
with time [4]. Several studies suggest that non-conjugated
polysaccharide vaccines may not contribute to adequate
protection against non-invasive pneumonia [14, 15], while
their efficacy in preventing invasive pneumonia in elderly
patients and adults with co-morbidities remains limited [14,
16, 17]. Conjugated vaccines are able to induce functional
antibody response (T cell dependent) directed to the bac-
terial capsule, resulting in a robust initial response and in
the establishment of immunological long-lived memory
[18, 19]. In children, conjugated pneumococcal vaccines
have been shown to be highly effective in preventing both
IPD and pneumonia caused by the vaccine-related ser-
otypes [20]; however, data concerning the impact in adults
and high-risk populations are scarce [14].
After the introduction and widespread use of PCV13 in
the infant population, on 3 March 2015 it was approved for
the prevention of pneumonia and invasive disease caused
by S. pneumoniae in the adult population [21]. At present,
there is no evidence available regarding the cost effec-
tiveness of pneumococcal immunization with conjugate
vaccines in adult patients at increased risk of PD in Spain.
The aim of this analysis was to evaluate the clinical and
economic consequences of the use of a single dose of
PCV13 among the COPD adult population aged C50 years
compared with CVP based on PPV23.
2 Materials and Methods
2.1 Model Description
A model with a Markov process based on the following
health states was developed in Microsoft Excel 2007 to
depict the risks and costs of IPD and all-cause NBP in
a C50-year-old Spanish COPD population: alive without
IPD or all-cause NBP; alive with IPD; alive with all-cause
inpatient NBP; alive with all-cause outpatient NBP; and
death (Fig. 1). All patients entered the model in the non-PD
state. Therefore, the risks of developing IPD (such as
meningitis and bacteremia, among others) and all-cause
NBP (outpatient or inpatient) were modeled. An age-
stratified cohort of patients with known underlying COPD
was included in the model according to the known preva-
lence of disease in Spain [22].
The expected total number of IPD cases and all-cause
NBP (by setting of care), expected number of deaths due to
IPD and all-cause inpatient NBP, expected total costs of
medical treatment for IPD and all-cause NBP, and total
costs of vaccination were evaluated. All expected outcomes
were evaluated on an annual basis, from model entry
through the end of the modeling horizon. In each year,
pneumococcal-related outcomes were projected for each
person in the model population based on age, risk profile,
and vaccination status.
Cost effectiveness was estimated based on the incre-
mental cost-effectiveness ratio (ICER), which was calcu-
lated by dividing the differences in costs by the quality-
adjusted life-years (QALYs) gained with a PCV13 strategy
versus CVP with PPV23. A QALY takes into account both
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the quantity and quality of life generated by healthcare
interventions. It is the arithmetic product of life expectancy
and a measure of the quality of the remaining life-years.
2.2 Vaccination Strategies
Two vaccination strategies were compared: the CVP con-
sisting of one dose of PPV23 at model entry, and an
alternative vaccination strategy with one dose of PCV13.
The pneumococcal vaccination strategy was estimated to
reach an annual coverage of 59.5 % of COPD patients in
the base-case scenario for subjects above 50 years old
(50–64 years: 41.1 %; 65–74 years: 62.9 %; 75–84 years:
69.4 %; 85–99 years: 71.8 % [23]), and was considered to
be equivalent for both vaccination strategies. The potential
herd effect from vaccinating the pediatric population in any
of the vaccination strategies analyzed was also considered
(see Table 1 for the herd protection effect in percentages).
Maximum values for herd effects were assumed to be
obtained in year 1 of the modeling horizon [24–26].
2.3 Patient Population
Population estimations were based on national figures from
the Spanish National Statistical Institute [9]. Stratification
was considered by the following age groups: 50–64, 65–74,
75–84, and C85 years. The population modeled included
629,727 Spanish adults aged C50 years with COPD. This
number considered the COPD prevalence by age group and
the proportion (26.9 %) of diagnosed COPD patients in the
Spanish population [22]. Subjects were assumed not to be
previously vaccinated at model entry.
2.4 Clinical Data
Risk-specific incidence and case fatality rates associated
with IPD were based on published data in chronic respi-
ratory disease [3], which concluded that the annual IPD
incidence for all age groups was 91 cases per 100,000
inhabitants. The all-cause NBP inpatient incidence rate was
taken from a Spanish database that collected hospitaliza-
tions due to several diseases, including pneumonia [27].
The incidence rate of all-cause outpatient NBP was esti-
mated by the proportion of outpatient pneumonia from the
total all-cause NBP (58.5 %) data [8]. Due to a lack of
local data, the division of NBP incidence by each of the age
groups was performed based on the proportion of NBP
(such as inpatient or outpatient) incidence by age group
observed in a surveillance program carried out by the US
Centers for Disease Control and Prevention [28]. The
annual all-cause COPD population mortality rate was
obtained from national statistics [9]. The IPD-related
mortality was based on specific chronic respiratory disease
published data [3]. The all-cause inpatient NBP mortality
rate was estimated based on the data published by Merino-
Sa´nchez et al. [29] and divided by age group. All clinical
and epidemiology data are summarized in Table 1.
2.5 Vaccine Effectiveness
The effectiveness of both pneumococcal vaccines depen-
ded on immunization level, vaccine efficacy in IPD and
non-IPD differentiated by age and risk groups, vaccine
coverage, serotype coverage, and duration of protection
[30]. As the COPD population were considered to be at-
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risk but immunocompetent individuals, the data for PPV23
effectiveness against IPD were obtained from an investi-
gation that aimed to evaluate the epidemiological impact of
the PPV23 vaccination program in the elderly in England
and Wales [31]. The effectiveness of PPV23 against all-
cause NBP was assumed to be zero based on published
meta-analyses and systematic reviews [14]. For PCV13,
effectiveness data for both IPD and pneumonia in the adult
immunocompetent population was taken from CAPiTA
(Community-Acquired Pneumonia Immunization Trial in
Adults), which was performed in The Netherlands in adults
aged C65 years not previously vaccinated against S.
pneumoniae [32]. Effectiveness of the vaccine decreased
with age in both strategies and a waning effect over time
was considered for all age groups. All effectiveness data
used in the model are given in Table 2 as they appeared in
the mentioned sources [31, 32]. The coverage of vaccine
serotypes for IPD was 76.5 and 70.0 % for PPV23 and
PCV13, respectively [33] and for any-cause NBP either
requiring inpatient or outpatient care was 19.4 % for
PCV13 using the serotype-specific urinary antigen detec-
tion assay [34].
2.6 Utilities
Self-assessed health state (or utility) scores measure an
individual’s preferences for specific outcomes and were
used to calculate QALYs. Estimations of age-/risk-specific
health-state utility and disutility values due to disease were
based on published studies. Health-state utilities for the
COPD general population by age group were 0.8101
(50–64 years old), 0.7542 (65–74 years old), 0.6792
(75–84 years old), and 0.5280 (85–99 years old) [35].
Also, reductions in health-state utility values due to disease
were considered in the model: IPD (–0.076), inpatient NBP
(–0.079), and outpatient NBP (–0.004) [36, 37].
2.7 Costs
Medical costs considered in this model were bacteremia,
meningitis, and all-cause NBP (inpatient and outpatient)
management costs. Management costs of PD were obtained
from the literature [8, 38]. The pharmacy retail price [39]
adjusted with a 7.5 % mandatory deduction [40] was used
to estimate vaccine costs. Administration costs for both
CVP and PCV13 were assumed to be zero as they were
supposed to be administered together with the influenza
vaccine. All costs are presented in euros (€) adjusted to
2015 prices, using appropriate price inflation rates when
required (Table 3).
2.8 Time Horizon, Perspective, and Discount Rate
A lifetime horizon (82 years maximum) was adopted for
the base case, following all patients until death. The
analysis considered the perspective of the Spanish National
Table 1 Vaccine coverage,
incidence, mortality rates, and
herd protection effects used in
the model
Age group (years)
50–64 65–74 75–84 85–99
Vaccine coverage (%) (COPD subjects) [22] 41.1 62.9 69.4 71.8
Incidence rates (/100,000)
IPD [3] 91.0 91.0 91.0 91.0
Outpatient NBP [8, 28] 143.2 422.0 1089.0 2476.5
Inpatient NBP [8, 28] 201.8 594.9 1535.1 3491.0
Mortality rates (%)
General population [9] 0.74 1.66 5.98 14.27
IPD [3] 18.30 32.90 32.90 32.90
Patients with inpatient NBP [8] 7.08 8.00 12.32 20.61
Herd protection effects (%)a
IPD [23] 33.0 28.2 30.3 20.8











% of maximum herd effects due to widespread use of PCV13 in
young children, by year of modeling horizon
58.0 72.0 85.0 92.0 100.0
COPD chronic obstructive pulmonary disease, IPD invasive pneumococcal disease, NBP non-bacteremic
pneumonia, PCV13 13-valent pneumococcal conjugate vaccine
a Expressed as the maximum reduction in disease due to active widespread immunization use with PCV13
in young children in Spain
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Healthcare System (NHS); thus, only direct healthcare
costs (cost of vaccines only) were included. Costs and
health benefits were both discounted at 3.0 % annually, as
counseled by the latest Spanish recommendations for
development of economic evaluations [41].
2.9 Uncertainty Management and Sensitivity
Analyses
Inherent variability in the population of interest was man-
aged in the base case by applying a probabilistic sensitivity
analysis (PSA), in order to get population-specific values
based on probabilities for the previously described
parameters. A Monte-Carlo simulation was used to assess
the uncertainty of incidence and mortality rates, vaccine
effectiveness, and medical costs. The distributions used to
simulate these parameters were beta distribution for inci-
dence and mortality rates and vaccine effectiveness, Log-
normal distribution for cost and uniform for utility values
and herd effect (Table 4). The PSA was run for 1000
iterations and a cost-effectiveness acceptability curve was
plotted in terms of the probability of net monetary benefit is
above 0 for different willingness-to-pay thresholds.
Additionally, one-way deterministic sensitivity analyses
were also performed, involving modification of values for
some specific parameters not related to inter-sample vari-
ation. Parameters that were modified were the time horizon
(5, 10, and 20 years), discount rate (undiscounted and 5 %
for both outcomes and costs), revaccination at 5 years for
56.4 % with CVP only, vaccination coverage based on an
influenza vaccination program for the general population
instead of COPD patients (based on the Spanish National
Health Survey [23]), inclusion of only the COPD popula-
tion C65 years, serotype coverage of immunocompro-
mised subjects (64.2 % PPV23 and 44.1 % for PCV13;
based on a Spanish publication [33]), waning effect (de-
creasing by an additional 15 %) only for PCV13, the cost
of outpatient pneumonia including the healthcare compo-
nent only (€349.74) and ±25 % variation in indirect effect,
utility values, vaccine effectiveness, disease incidences,
and mortality. Finally, the vaccine price for both PPV23
and PCV13 was reduced by 15 % separately.
Table 2 Vaccine effectiveness by age group (%)
PCV13 effectiveness by no. of years since receipt of vaccine
[32]
PPV23 effectiveness by no. of years since receipt of vaccine [14,
31]
0 1–5 6–10 11–15 [15 0 1–5 6–10 11–15 [15
IPD by age (years)
50–64 82.0 80.9 53.3 21.0 19.3 87.3 69.0 22.8 2.7 0.7
65–74 76.8 74.5 41.0 13.8 12.7 76.6 54.1 12.3 0.9 0.2
75–84 72.2 68.5 27.7 4.5 4.1 67.8 41.3 4.5 0.1 0
C85 67.6 61.5 1.1 0 0 59.4 28.8 0 0 0
Inpatient NBP by age (years)
50–64 9.5 9.4 6.2 2.4 2.2 0 0 0 0 0
65–74 8.9 8.7 4.8 1.6 1.5 0 0 0 0 0
75–84 8.4 8.0 3.2 0.5 0.5 0 0 0 0 0
C85 7.9 7.2 0.1 0 0 0 0 0 0 0
Outpatient NBP by age (years)
50–64 9.5 9.4 6.2 2.4 2.2 0 0 0 0 0
65–74 8.9 8.7 4.8 1.6 1.5 0 0 0 0 0
75–84 8.4 8.0 3.2 0.5 0.5 0 0 0 0 0
C85 7.9 7.2 0.1 0 0 0 0 0 0 0
IPD invasive pneumococcal disease, NBP non-bacteremic pneumonia, PCV13 13-valent pneumococcal conjugate vaccine, PPV23 23-valent
pneumococcal polysaccharide vaccine
Table 3 Unit costs
Costs (€; 2015 values)
PCV13 (Prevenar 13) 47.04/prefilled syringe [39]
PPV23 (Pneumo 23) 8.70/prefilled syringe [39]
Management disease costs
IPD 5827.30 [38]
Inpatient NBP 4647.03 [8]
Outpatient NBP 620.85 [8]
IPD invasive pneumococcal disease, NBP non-bacteremic pneumo-
nia, PCV13 13-valent pneumococcal conjugate vaccine, PPV23
23-valent pneumococcal polysaccharide vaccine
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3 Results
The administration of PCV13 to the Spanish COPD
cohort C50 years, under base-case assumptions, would
account for higher health benefits than CVP with PPV23
(Fig. 2). Overall, compared with CVP the inclusion of one
dose of PCV13 would avoid 210 IPD cases, 2224 inpatient
NBP cases, and 3134 outpatient NBP cases for a lifetime
horizon. Additionally, 398 related deaths would be averted.
Medical plus vaccination costs per patient obtained in the
model would imply a cost of €682 and €686 for CVP and
PCV13, respectively, for the NHS in a lifetime period. In
addition, the total survival gain in terms of life-years
gained (LYG) and QALYs would be slightly higher with
PCV13 vaccination than with CVP per COPD-assessed
patient, with a mean increase of 0.0036 LYG and 0.0024
QALYs. Costs and outcomes results per patient are shown
in Table 5. The resulting ICER was €1245 per additional
Table 4 Probabilistic sensitivity analysis parameters
IPD Inpatient NBP Outpatient NBP Distribution
Mean
value




50- to 64-year-olds 90.80 149.16 163,761.85 143.00 234.72 163,676.29 201.60 330.77 163,580.23 Beta
65- to 74-year-olds 90.84 183.69 201,675.92 421.84 851.85 201,007.77 594.71 1200.80 200,658.81
75- to 84-year-olds 90.82 170.60 187,298.02 1088.83 2041.53 185,427.08 1534.93 2877.83 184,590.79
85- to 99-year-olds 90.57 69.62 76,438.61 2476.10 1894.73 74,613.50 3490.57 2670.89 73,837.35
Case fatality rate
50- to 64-year-olds 18.30 29,995.71 133,915.29 7.08 11,611.54 152,299.47 Not applicable Beta
65- to 74-year-olds 32.90 66,411.81 135,447.80 8.00 16,148.77 185,710.85
75- to 84-year-olds 32.90 61,677.18 125,791.44 12.32 23,097.87 164,370.74
85- to 99-year-olds 32.90 25,171.21 51,337.03 20.61 15,770.52 60,737.72













5827.3 2476.12 4647.03 547.66 620.85 73.17
Indirect effects ±10 % Uniform
Utilities ±10 % Uniform
Disease-related disutility ±10 % Uniform
Fig. 2 Clinical results for a
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LYG and €1844 per QALY gained for PCV13 compared
with CVP with PPV23. All ICERs obtained by age group
were less than €10,000/QALY. For the 75–84 and
85–99 years age groups, PCV13 would be the dominant
alternative versus CVP.
3.1 Sensitivity Analysis
Since some model variables, such as vaccine effectiveness,
were inferred, different scenarios were assessed to further
investigate the relationship between parameters and cost-
effectiveness results and to confirm the robustness of the
model. PSA results revealed that the PCV13 vaccination
strategy was a cost-effective option in 100 % of 1000
simulations performed (Fig. 3). Univariate sensitivity
analyses results are included in Fig. 3 and Table 6. Results
from sensitivity analyses on previously mentioned param-
eters did not substantially affect the results, with all sce-
narios indicating that use of PCV13 in COPD patients
aged C50 years was cost effective (Table 6). The most
sensitive parameter was vaccine effectiveness, with a
reduction in PCV13 effectiveness either in IPD or inpatient
pneumonia producing the highest variation in ICER values.
In particular, a 25 % decrease in PCV13 effectiveness in
IPD would increase the ICER (€29,055) close to the will-
ingness-to-pay threshold cost-effectiveness value that
exists in Spain. In contrast, a 25 % reduction in PPV23
effectiveness in IPD would produce a dominant situation
favoring PCV13. The rest of the modified parameters
showed that the cost-effectiveness analysis results are
robust to a variety of alternatives scenarios. Even
increasing vaccination coverage to 100 % of the identified
COPD cohort would also result in a cost-effective strategy
reporting an ICER of €2499/QALY (Fig. 4). Another
influential parameter was time horizon since the scenario of
a 5-year horizon showed an ICER of €25,573/QALY.
Nonetheless, in this scenario, PCV13 vaccination would
still be associated with 1302 inpatient NBP cases, 1835
outpatient NBP cases, and 182 deaths prevented versus
PPV23 vaccination (see Table 6). Finally, the vaccine price
was sensitive to variation in cases where the PCV13 price
was reduced by 15 %, as this scenario showed PCV13 to be
Table 5 Lifetime results
PPV23 PCV13 vaccination Incremental (PCV13 vs. CVP)
Total costs per patient (€) 682 686 4
50–64 years 585 596 11
65–74 years 698 706 8
75–84 years 744 743 –1
85–99 years 689 683 –6
Total effectiveness per patient (QALYs) 7.5913 7.5937 0.0024
50–64 years 12.8229 12.8240 0.0011
65–74 years 8.1214 8.1238 0.0023
75–84 years 4.5680 4.5712 0.0032






Total effectiveness per patient (LYG) 10.9715 10.9751 0.0036
50–64 years 17.0772 17.0787 0.0015
65–74 years 11.7440 11.7473 0.0032
75–84 years 7.4219 7.4269 0.0050






CVP current vaccination policy, ICER incremental cost-effectiveness ratio, LYG life-years gained, QALYs quality-adjusted life-years, PCV13
13-valent pneumococcal conjugate vaccine, PPV23 23-valent pneumococcal polysaccharide vaccine
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a dominant option. However, the same reduction of price
for PPV23 showed a 27 % increase in the ICER for
PCV13, which could still be considered highly cost effec-
tive in Spain.
4 Discussion
In Spain, pneumococcal vaccination with PPV23 is cur-
rently funded by the NHS and recommended for adults
with certain chronic conditions. The cost effectiveness of
PCV13 vaccination of individuals aged C50 years with
COPD was assessed in comparison with the existing pol-
icy. All scenarios analyzed in the model suggest that, from
the Spanish NHS perspective, a routine pneumococcal
adult vaccination scheme with PCV13 would be a highly
cost-effective intervention. Under base-case analysis, a
PCV13 policy would cost €1844 per additional QALY
versus CVP. Other model parameters included in the
deterministic sensitivity analysis impacted the final ICER,
but in all cases, and assuming the common willingness-to-
pay threshold in Spain of around €30,000 per additional
QALY [42], provision of a single dose of PCV13 to the
Spanish cohort with COPD aged C50 years would be
considered a cost-effective strategy compared with CVP
with PPV23 from the NHS perspective.
The most influential parameters were vaccine effec-
tiveness on IPD, time horizon, and vaccine price. Herd
effect, even considering high values that are out of the
scope of the Spanish situation regarding vaccination
policy in childhood (still very limited), was of little
impact in the model, with only small differences found
between the ±25 % variation and the value included in
the base-case scenario. A 25 % reduction in PCV13
effectiveness on IPD would be accompanied by an ICER
increment close to the willingness-to-pay threshold cost-
effectiveness value existing in Spain of around €30,000/
QALY [42]. On the other hand, a 25 % reduction of
PPV23 effectiveness on IPD would produce a dominant
situation (lower cost and higher clinical benefits) favoring
PCV13. A PCV13 vaccination strategy versus CVP over a
lifetime horizon resulted in an ICER of €1844 per QALY
gained that is clearly below the commonly accept-
able threshold used to determine the cost-effectiveness
profile of a health technology in Spain [42]. It is worth
highlighting that crucial outcomes for prophylactic mea-
sures are referred to using averted cases, and in all PD
types assessed in this research a PCV13 vaccination
strategy scenario compared with CVP would avoid 2224
inpatient NBP, 3134 outpatient NBP, and 210 IPD cases.
In cost terms, for the lifetime horizon, the results of this
study suggest that use of PCV13 would lead to a reduc-
tion in the total number of cases of PD as well as a cost
reduction via avoided healthcare services that would
partially offset the incremental costs related to PCV13
vaccination in adults aged C50 years. Finally, while a
15 % reduction in the PCV13 price was associated with a
dominant situation in favor of this vaccination strategy,
the same reduction for PPV23 had little effect on the
ICER value.
To date, several economic PCV13 evaluations have
been published in other settings [20, 30, 43–56]. Published
Fig. 3 Sensitivity analysis—tornado diagram. COPD chronic
obstructive pulmonary disorder, ICER incremental cost-effectiveness
ratio, IPD invasive pneumococcal disease, PCV13 13-valent
pneumococcal conjugate vaccine, PPV23 23-valent pneumococcal
polysaccharide, QALY quality-adjusted life-years gained
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Table 6 Univariate sensitivity analysis results
Parameter BC value SA value ICER (€/QALY) Variation with
BC (%)
BC 1844
Time horizon Lifetime 5 years 25,573 1,287
10 years 3547 92
20 years 1958 6
Discount rate 3 % for outcomes and
costs
Undiscounted 587 –68
5 % for outcomes and costs 2901 57
Revaccination No revaccination 56.4 % revaccination with CVP at
5 years
2497 35
Vaccination coverage 41.1/62.9/69.4/71.8 %a General population values: 18.9/
49.3/65.6/67.3 %a
1203 –35
100 % 2499 36
COPD population C50 years C65 years 769 –58
IPD serotype coverage 76.5 % PPV23 and
70.0 % PCV13
64.2 % PPV23 and 44.1 %
PCV13b
3603 95
Waning effect - –15 % of BC of PCV13 2853 55
Indirect effect IPD –25 %; ?25 % 1605; 1930 –13;5
In/out-patient
pneumonia
–25 %; ?25 % 1730; 1883 –6;2
Disease incidence IPD –25 %; ?25 % 2607; 1630 41; –12
In-patient pneumonia –25 %; ?25 % 16,627; 317 783; –83
Out-patient pneumonia –25 %; ?25 % 2718; 1555 47; –18
Mortality General population –25 %; ?25 % Dominant; 2778 NA; 51
IPD –25 %; ?25 % 2063; 1782 12; –3
In-patient pneumonia –25 %; ?25 % 3688; 1609 100; –13
Utility General utility –25 %; ?25 % 5439; 1511 195; –18
Disutility due to IPD –25 %; ?25 % 1856; 1841 1; –1
Disutility in in-patient
pneumonia
–25 %; ?25 % 1999; 1798 8; –3
Disutility in out-patient
pneumonia
–25 %; ?25 % 1855; 1841 1; –1
Vaccine effectiveness PPV23 in IPD –25 %; ?25 % Dominant; 3342 NA; 81
PCV13 in IPD –25 %; ?25 % 29,055; 709 1,476; –62
PCV13 in in-patient
pneumonia
–25 %; ?25 % 17,056; 268 825; –86
PCV13 in out-patient
pneumonia
–25 %; ?25 % 2736; 1549 48; –16
Medical costs IPD –25 %; ?25 % 2309; 1689 25; –8
In-patient pneumonia –25 %; ?25 % 6406; 324 247; –82
Out-patient pneumonia –25 %; ?25 % 2703; 1558 47; –16
Out-patients pneumonia cost including
healthcare component only
620.85 349.74 2344 27








BC base case, COPD chronic obstructive pulmonary disease, CVP current vaccination policy, ICER incremental cost-effectiveness ratio, NA not
applicable, QALY quality adjusted-life year, SA sensitivity analysis, ENSE Spanish National Health Survey year’s 2011/2012
a Age groups, respectively: 50–64, 65–74, 75–84 and 85–99 years
b Values correspond to immunocompromised subjects according to Andrews et al. [31]
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cost-effectiveness analyses are available for the USA,
England, Germany, Italy, and The Netherlands, with a wide
range of immunization strategies and different populations
tested. Comparison of results between studies is difficult
because of model assumptions, differences in healthcare
system organizations, epidemiology, year of cost values,
and other country-specific factors, but some of them can be
mentioned as illustrative examples. In the USA, PCV13
was dominant (higher effectiveness with lower cost) when
the cost effectiveness of the addition of one dose of PCV13
to the previously recommended PPV23 dose in adults with
selected immunocompromising conditions was explored
[44], and was more cost effective than PPV23 in
immunocompromised or older adults [46, 47]. Routine
PCV13 at ages 50 and 65 years yielded a $US45,100 per
QALY ratio compared with current recommendations in
the USA [50]. At a European level, PCV13 was dominant
in Italy [45] for immunization of the at-risk population
50–79 years, and in Germany it was dominant for adults
([18 years) [53]. Most recently, cost-utility analyses in
The Netherlands [54] and Italy [49] reported that PCV13
vaccination in adults aged[65 years is cost effective. In
England [51], however, the yielded ratio of vaccinating
people ([2 years old) with high-risk conditions against
IPD using PCV13 was above £30,000 (€37,216) per
QALY, and some studies suggested that use of PCV13 in
the elderly or adult at-risk population could affect health-
care budgets in Germany [55] and the UK [56].
The model structure of the present work has been used
previously to estimate the cost effectiveness of PCV13 in
other frameworks such as in a study in the USA [43], which
concluded that the administration of one dose of PCV13 in
adults C50 years would result in a great reduction in the
overall burden of PD, being a dominant strategy compared
with PPV23 [43].
Despite these studies, it is important to note that this is
the first evaluation addressing the question of cost effec-
tiveness for conjugate pneumococcal vaccination that is
specially focused in COPD adults and applying the vaccine
efficacy data from the CAPiTA trial [32]. Therefore, no
comparison with other studies in a similar population is
feasible.
The present study has some limitations and assumptions
to be considered. In the absence of efficacy data for
pneumococcal pneumonia in an ambulatory care setting,
we assumed similar efficacy as in the inpatient setting.
Given that more than half of COPD patients who develop
pneumonia are treated in an inpatient setting and the cost of
hospitalization is a key cost driver, the impact of such an
assumption is likely to be minimal. Some parameters such
as the waning of vaccine protection in the long-term and
indirect effects are uncertain. However, a conservative
estimate for indirect effects was employed for the base-
case scenario and sensitivity analyses for waning effect
confirmed the robustness of the results. The present model
was developed from a third-party payer perspective; thus, it
did not include indirect costs that could be useful for a
societal analysis. It is difficult to incorporate reliable data
derived from PD in terms of indirect costs. However, the
inclusion of indirect costs would lead to a lower ICER, as
the working-age population (50–64 years) is expected to
have less work loss due to pneumococcal pneumonia. Also,
one could argue that PCV13 had little gain in terms of
QALY measurement (only 0.0024 per patient), but also the
incremental cost was negligible (less than €4 and even
dominant in older groups). Finally, Spanish evidence on
the incidence and case-fatality rate in PD is lacking in this
specific group of patients considered. Nevertheless, data
from COPD patients in the UK applied in the model would
not differ substantially from the Spanish COPD population
Fig. 4 Model acceptability
curve. PCV13 13-valent
pneumococcal conjugate
vaccine. Red line represents the
willingness-to-pay cost
effectiveness threshold
currently accepted in Spain
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due to similarities in healthcare organizations and patient
management in both countries.
5 Conclusion
Based on reasonable assumptions regarding PCV13 and
PPV23 effectiveness as well as the available epidemio-
logical and cost data, the use of one dose of PCV13 for
COPD patients aged C50 years, instead of CVP with
PPV23, is expected to lead to a decline in IPD, inpatient
and outpatient NBP cases, and their related deaths. Fur-
thermore, the incremental costs of this vaccination strategy
are counterbalanced in part by savings from averted PD
cases. The proposed vaccination strategy is a highly cost-
effective option compared with current vaccination with
PPV23 based on the accepted Spanish cost-effectiveness
threshold of €30,000 per QALY over a lifetime horizon
from the NHS perspective.
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